Skye Bioscience (SKYE) Appoints Paul Grayson as Chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- IBM surges on unveiling sub-1nm chip technology breakthrough
- 'Long-term deals significant positive for stock:' Analysts react to Micron results
- Two major earthquakes strike Venezuela, killing at least 32 and injuring hundreds
- Needham Starts NeoVolta (NEOV) at Buy
- Hertz cuts guidance, announces notes and stock offerings, shares sink
- Rockstar Games opens GTA VI pre-orders, priced at $79.99
- Rubio meets Gulf leaders, pledges security amid Iran deal doubts
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
October 29, 2024 7:00 AM EDTSAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (Skye), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skyes new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skyes Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skyes Chief Executive Officer, will continue to serve as a member of the Board.
Punit Dhillon, Skyes Chief Executive Officer and former Chairman of the... More
